Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
International Stem Cell Corporation develops stem cell-based biomedical products for therapeutic and research applications.
International Stem Cell Corporation is a small biotech company that works with stem cells — the blank-slate cells in our bodies that can turn into many different kinds of tissue. It develops cell-based products aimed at both medical treatment and laboratory research, and it sells those products to researchers and drug developers rather than to everyday consumers.
The company's scientific bet centers on a particular kind of stem cell it calls "parthenogenetic" stem cells. The idea is to create stem cell lines from unfertilized human eggs, which sidesteps some of the ethical controversy that surrounds embryo-derived cells. If it works, this approach could give researchers a ready supply of cells for studying disease and testing potential treatments. For years the company has funded its research partly through its commercial side — selling specialized cell-culture products to labs and universities that need human cells to do their experiments. That revenue is modest, and the business has consistently lost money while it pours cash into research. It is a speculative, thinly traded company on the OTC Pink market, which means it carries real risk and little of the scrutiny that comes with a major exchange listing.
The basic attraction and the basic problem are the same: stem cell medicine could eventually treat serious diseases, but turning that promise into approved products takes years and enormous amounts of money. Investors in International Stem Cell Corporation are essentially betting on the science panning out — a long shot with genuine upside if it does.
Saved answer · last researched 16 Nov 2026